These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 28090673)
1. Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. Dorey L; Pelligand L; Cheng Z; Lees P J Vet Pharmacol Ther; 2017 Oct; 40(5):505-516. PubMed ID: 28090673 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. Dorey L; Pelligand L; Cheng Z; Lees P PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968 [TBL] [Abstract][Full Text] [Related]
3. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling. Dorey L; Pelligand L; Lees P BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426 [TBL] [Abstract][Full Text] [Related]
4. Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens. Dorey L; Lees P BMC Vet Res; 2017 Jun; 13(1):192. PubMed ID: 28645327 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. Lees P; Potter T; Pelligand L; Toutain PL J Vet Pharmacol Ther; 2018 Feb; 41(1):28-38. PubMed ID: 28736817 [TBL] [Abstract][Full Text] [Related]
6. Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media. Dorey L; Hobson S; Lees P Res Vet Sci; 2017 Apr; 111():43-48. PubMed ID: 27940285 [TBL] [Abstract][Full Text] [Related]
7. What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida? Dorey L; Hobson S; Lees P J Vet Pharmacol Ther; 2017 Oct; 40(5):517-529. PubMed ID: 28101885 [TBL] [Abstract][Full Text] [Related]
8. Activity of florfenicol for Actinobacillus pleuropneumoniae and Pasteurella multocida using standardised versus non-standardised methodology. Dorey L; Hobson S; Lees P Vet J; 2016 Dec; 218():65-70. PubMed ID: 27938711 [TBL] [Abstract][Full Text] [Related]
9. Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. Dorey L; Hobson S; Lees P Res Vet Sci; 2017 Apr; 111():93-98. PubMed ID: 28113129 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic integration and modelling of florfenicol in calves. Sidhu P; Rassouli A; Illambas J; Potter T; Pelligand L; Rycroft A; Lees P J Vet Pharmacol Ther; 2014 Jun; 37(3):231-42. PubMed ID: 24341543 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. Lees P; Pelligand L; Illambas J; Potter T; Lacroix M; Rycroft A; Toutain PL J Vet Pharmacol Ther; 2015 Oct; 38(5):457-70. PubMed ID: 25669418 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of doxycycline and oxytetracycline against porcine respiratory pathogens. Bousquet E; Morvan H; Aitken I; Morgan JH Vet Rec; 1997 Jul; 141(2):37-40. PubMed ID: 9253829 [TBL] [Abstract][Full Text] [Related]
13. Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine. Sun D; Mi K; Hao H; Xie S; Chen D; Huang L BMC Vet Res; 2020 Sep; 16(1):366. PubMed ID: 32993661 [TBL] [Abstract][Full Text] [Related]
14. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis. Blondeau JM; Fitch SD PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633 [TBL] [Abstract][Full Text] [Related]
15. Optimizing tylosin dosage for co-infection of Lee EB; Abbas MA; Park J; Tassew DD; Park SC Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic integration and modelling of marbofloxacin in calves for Mannheimia haemolytica and Pasteurella multocida. Potter T; Illambas J; Pelligand L; Rycroft A; Lees P Vet J; 2013 Jan; 195(1):53-8. PubMed ID: 23084327 [TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine. Inamoto T; Kikuchi K; Iijima H; Kawashima Y; Nakai Y; Ogimoto K J Vet Med Sci; 1994 Oct; 56(5):917-21. PubMed ID: 7865594 [TBL] [Abstract][Full Text] [Related]
18. Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model. Wang H; Liao C; Ding K; Zhang L; Wang L BMC Vet Res; 2024 Jun; 20(1):241. PubMed ID: 38831324 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Salmonella choleraesuis isolates from pigs. Raemdonck DL; Tanner AC; Tolling ST; Michener SL Vet Rec; 1994 Jan; 134(1):5-7. PubMed ID: 8128570 [TBL] [Abstract][Full Text] [Related]
20. Antimicrobial resistance genes in Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida isolated from Australian pigs. Dayao D; Gibson JS; Blackall PJ; Turni C Aust Vet J; 2016 Jul; 94(7):227-31. PubMed ID: 27349882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]